Entity

Time filter

Source Type

United States

Naylor S.,D2D Inc. | Naylor S.,MaiHealth Inc. | Cole T.,D2D Inc. | Cole T.,Triad Group
Drug Discovery World | Year: 2010

There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools as well as the portent of relevant biological and clinical information that addresses many of the current problems that pharmaceutical companies must overcome. This in concert with the advent of personalised medicine and the demise of the therapeutic drug 'Blockbuster Model' has necessitated a re-evaluation of the pharmaceutical business model. The outcome of such considerations will be determined, in part, by the changing landscape, and influence of the various stakeholders associated with the pharmaceutical sector, including patients/consumers, physicians and healthcare providers, payors and Companion Diagnostic companies. In this paper we describe the difference in perceived value that each key stakeholder holds in regards to the pharmaceutical drug versus the Companion Diagnostic test. We also discuss the perspectives of both the pharmaceutical and Companion Diagnostic companies as they struggle to find appropriate business models. Such models must serve their individual company needs in terms of product value as well as support the very necessary collaborative efforts required to co-develop a therapeutic drug in conjunction with a Companion Diagnostic.


Naylor S.,D2D Inc. | Cole T.,D2D Inc.
Drug Discovery World | Year: 2010

Current escalating costs of drug discovery, development and drug launch continue to concern the pharmaceutical sector. This has been compounded by the advent of personalised medicine and its associated demands for individualised products as well as the demise of the 'blockbuster' model. In order to satisfy the demands afforded by this new paradigm, the next generation of drugs has to be safer and more efficacious and pharmaceutical companies must produce more genotype and/or phenotype-focused therapeutic agents. The development of Companion Diagnostics appears to offer a set of tools as well as the portent of relevant biological and clinical information that addresses many of the problems that the pharmaceutical companies must overcome. Here, we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector. We discuss the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented by a consideration of the development of Companion Diagnostics as well as a listing of the major companies providing tools, technologies, markers and services in this rapidly growing area.

Discover hidden collaborations